Advertisement
Product › Details
TG4010 (MVA-MUC1-IL2) (Transgene)
Next higher product group | MVA-Muc1-IL2 cancer vaccine | |
Status | 2007-05-01 development p2 existent | |
Organisation | Transgene S.A. (Euronext: TNG) | |
Group | Mérieux (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for TG4010 (MVA-MUC1-IL2) (Transgene)
- [1] Transgene S.A.. (9/13/17). "Press Release: First Half-year 2017 in Line with Our Objectives – All Clinical Programs Progressing and New Collaboration Agreements Signed". Strasbourg....
- [2] Transgene S.A.. (9/11/17). "Press Release: Transgene Receives FDA IND Approval to Begin a Clinical Trial with TG4010 + Nivolumab + Chemotherapy in the First-Line Treatment of Lung Cancer (NSCLC)". Strasbourg....
- [3] Transgene S.A.. (4/25/17). "Press Release: Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer". New York, NY & Stras...
- [4] Transgene S.A.. (4/10/17). "Press Release: Transgene Announces Upcoming Investor Meetings and R&D Day". Strasbourg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top